TransMedics Completes PAD Aviation Investment to Expand in Europe
TMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.
TMDX - TransMedics Group, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$116.00
DETAILS
HIGH:
$142.00
LOW:
$80.00
MEDIAN:
$122.00
CONSENSUS:
$116.00
UPSIDE:
62.85%
Stock News
Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logistics
Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%.
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe ANDOVER, Mass., July 6, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.
Where Will TransMedics Group Stock Be in 10 Years?
TransMedics is building more than a medical device business. Its Organ Care System and nationwide transplant logistics network create a difficult-to-replicate competitive advantage.
3 Growth Stocks to Buy on the Dip
Investing in attractive stocks on the dip is a great way to earn above-average returns over the long run. The three stocks below have faced some challenges, but their prospects look fairly strong.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
What a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock Drop
Specializing in organ preservation technology, this medical device innovator reported a notable insider sale amid ongoing sector challenges.
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.
TransMedics: Why I'm Still Bullish After The Collapse
TransMedics (TMDX) faces decelerating revenue growth, margin pressure, and increased investment, yet maintains strong market share gains and competitive positioning. TMDX's logistics and clinical services now comprise nearly 40% of revenue, enhancing competitive advantages and supporting long-term margin strength. Despite growth normalizing to 20-25% and compressed margins, I see current valuation at 4x EV/Sales as attractive, supporting a Buy rating.
3 Growth Stocks Worth $5,000 of Your Money -- Even in This Market
Credo, Cellebrite, and TransMedics are building dominant positions in huge markets with years of expansion still ahead.
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge
TransMedics (TMDX +1.19%) has been hit hard as investors question margins, spending, and execution. But beneath the sell-off, the company's Organ Care System, aviation network, and National OCS Program could be building a deeper transplant infrastructure moat than the market realizes.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
TransMedics: Despite Earnings Miss, Growth Story Remains Intact
TransMedics remains a 'Strong Buy' despite a 50% stock decline and Q1 2026 earnings miss, supported by robust long-term growth initiatives. TMDX's portfolio expansion includes CHOPS as a complementary offering and aggressive European NOP rollout, aiming to expand its addressable market. Q1 2026 revenue grew 21% year-over-year to $174 million, led by liver segment strength, though higher costs compressed margins and net income.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggregate of 24,848 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026.
TransMedics: Cheaper, But Still Priced For Perfection
TransMedics Group, Inc. remains a Sell as its valuation still bakes in near-perfect execution, despite the stock being nearly 40% cheaper since October. TMDX's valuation implies sustaining some combination of between 9–20% revenue growth and 9–17% free cash flow margins, which remains a high bar given current trends. Growth levers like CHOPS, international expansion, and potential OPO conversion are either hedges, slow-moving, or highly uncertain, making current valuation hard to justify.
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Price Targets
TransMedics price target lowered to $90 from $100 at Evercore ISI
$90.00
(was $70.77)
Daniel Markowitz
·
Evercore ISI
TransMedics price target raised to $80 from $75 at Stifel
$80.00
(was $73.22)
Stifel Nicolaus
TransMedics price target lowered to $75 from $85 at Stifel
$75.00
(was $68.94)
Thomas Stephan
·
Stifel Nicolaus
TransMedics price target lowered to $142 from $174 at Needham
$142.00
(was $73.84)
Needham
TransMedics price target lowered to $124 from $152 at Canaccord
$124.00
(was $94.93)
William Plovanic
·
Canaccord Genuity
TransMedics price target lowered to $120 from $160 at Piper Sandler
$120.00
(was $94.93)
Piper Sandler
TransMedics price target lowered to $85 from $130 at Stifel
$85.00
(was $94.93)
Thomas Stephan
·
Stifel Nicolaus
TransMedics price target lowered to $140 from $157 at Baird
$140.00
(was $94.93)
David Rescott
·
Robert W. Baird
TransMedics price target raised to $130 from $115 at Stifel
$130.00
(was $134.77)
Stifel Nicolaus
TransMedics price target raised to $148 from $147 at Canaccord
$148.00
(was $125.04)
Canaccord Genuity
TransMedics price target raised to $166 from $148 at Needham
$166.00
(was $136.51)
Needham
TransMedics price target raised to $135 from $123 at Morgan Stanley
$135.00
(was $150.42)
Morgan Stanley
TransMedics price target lowered to $140 from $145 at Piper Sandler
$140.00
(was $134.32)
Matt O'Brien
·
Piper Sandler
TransMedics Group (TMDX) PT Raised to $147 at Canaccord Genuity
$147.00
(was $134.32)
Jason Mills
·
Canaccord Genuity
TransMedics upgraded to Buy from Hold at Needham
$148.00
(was $119.54)
Needham
TransMedics initiated with a Buy at Jefferies
$145.00
(was $107.29)
Jefferies
TransMedics added to 'Tactical Underperform' list at Evercore ISI
$155.00
(was $113.93)
Evercore ISI
TransMedics price target lowered to $120 from $150 at Baird
$120.00
(was $67.36)
David Rescott
·
Robert W. Baird
TransMedics price target lowered to $90 from $110 at Piper Sandler
$90.00
(was $67.36)
Matt O'Brien
·
Piper Sandler
TransMedics Group (TMDX) PT Lowered to $150 at Baird
$150.00
(was $88.70)
Joe Vruwink
·
Robert W. Baird